46 results on '"Deimling, A. von"'
Search Results
2. Imaging and diagnostic advances for intracranial meningiomas.
3. Molecular and translational advances in meningiomas
4. The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
5. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
6. Fluorescein-stained confocal laser endomicroscopy versus conventional frozen section for intraoperative histopathological assessment of intracranial tumors.
7. Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.
8. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in IDH mutant glioma
9. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma.
10. LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
11. BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma.
12. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
13. Diagnostic potential of extracellular vesicles in meningioma patients.
14. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
15. GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS
16. GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION
17. Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
18. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
19. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
20. IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING
21. IMMU-49. CYTOTOXIC T CELLS AND THEIR ACTIVATION STATUS ARE INDEPENDENT PROGNOSTIC MARKERS IN MENINGIOMAS
22. MPTH-23. LONG-TERM SURVIVAL WITH GLIOBLASTOMA IN THE ELDERLY
23. IMST-34. IMMUNOLOGICAL CHANGES DURING TUMOR PROGRESSION FROM PRIMARY TO RECURRENT GLIOBLASTOMA
24. OS2.1 Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas
25. OS2.3 A mutation-specific vaccination approach for Histon H3.3 K27M-mutated gliomas
26. OS2.4 Expression and relevance of tumoral and stromal MHC class II in gliomas
27. The molecular evolution of glioblastoma treated by gross total resection alone.
28. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
29. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
30. P07.04 Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study.
31. OS12.7.A Characterization of intra-tumoral heterogeneity and differential immune activation during malignant progression of meningiomas on single cell level.
32. OS11.5.A PATZ1 fusions define a novel molecularly distinct CNS tumor entity with a broad histological spectrum.
33. LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA.
34. OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas.
35. OS8.6 Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02.
36. GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS.
37. MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA.
38. MNGI-13. A DNA METHYLATION-BASED CLASSIFIER FOR ASSESSMENT OF RISK OF RECURRENCE IN MENINGIOMA.
39. ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA.
40. ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS.
41. P05.51 Prognostic impact of genetic alterations and methylation class in meningioma.
42. P04.79 Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas.
43. P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling.
44. P04.52 Spontaneous intratumoral T cell responses against glioblastoma-associated antigens.
45. P01.133 Preoperative predictors of malignancy in non-enhancing glioma in the era of molecular classification.
46. P01.031 VXM01 phase I study in patients with progressive glioblastoma - final results.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.